Delivery Order SPE2DB20D3104-SPE2DB25FV9C2
- Not listed
- The Defense Logistics Agency awarded a $1,036.20 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Mydayis ER 50 mg capsules (100 count). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 15, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Mydayis is an extended-release formulation used in the treatment of attention-deficit/hyperactivity disorder and represents...
- The Defense Logistics Agency awarded a delivery order valued at $4,773.28 to AmerisourceBergen Drug Corp for 100 capsules of MYDAYIS ER 50 mg, a prescription medication used to treat attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MYDAYIS ER 25 mg capsules (100-count units) valued at $1,061.94 under a firm fixed price contract. This non-set-aside delivery order was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. MYDAYIS is a prescription amphetamine-based medication used to treat...
- The Defense Logistics Agency awarded a $2,515.44 delivery order to AmerisourceBergen Drug Corp for 100 capsules of MYDAYIS ER 25 mg on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract for pharmaceutical supply performed at the contractor's Conshohocken, Pennsylvania location. MYDAYIS is an extended-release amphetamine-based medication used in the treatment of attention deficit hyperactivity disorder (ADHD). This delivery order...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,324.20 fixed-price delivery order is for the supply of the medication MYDAYIS ER 12.5 MG CAPSULE 100S, with a period of performance through March 2025. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This...
- This is a federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,975.53, is a delivery order for the supply of 100 units of the drug MYDAYIS ER 50 MG CAPSULE. The contract has an ultimate completion date of February 26, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count units) with a ceiling value of $1,189.40. This firm fixed-price delivery order, which is not set-aside, represents a competitive award executed under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical company AmerisourceBergen Corporation. The $1,419.34 contract is for the supply of 100 units of the drug MYDAYIS ER 25 MG CAPSULE. This delivery order falls under an existing $999,999,999.00 indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp to provide a comprehensive range of pharmaceutical products and medical...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical supplier. The $1,087.34 contract is for the supply of MYDAYIS ER 25 MG CAPSULE 100S to be delivered by March 6, 2024. Amerisourcebergen Drug Corp's Corporate Office in Conshohocken, Pennsylvania will be the place of performance. This delivery order is part of a larger...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,672.80 firm-fixed-price contract is for the supply of MYDAYIS CAPS 37.5MG, a prescription medication. The contract has an ultimate completion date of October 10, 2024. Amerisourcebergen, through its Corporate Office division, is a significant provider of pharmaceuticals and medical supplies to the U.S. federal...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FV9C2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mydayis ER 12.5 mg capsules (100 count) with a ceiling value of $3,185.52. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The order is scheduled for completion by July 25, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables comprehensive pharmaceutical and medical supply delivery to military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of federal contracts with DLA covering a broad range of pharmaceutical products across multiple therapeutic domains. This delivery order for Mydayis ER—a treatment for attention deficit hyperactivity disorder—is consistent with AmerisourceBergen's role as a primary pharmaceutical supplier supporting military and veteran healthcare delivery. All reviewed contract awards with this vendor have been competitively awarded with firm fixed pricing, demonstrating the company's capability to meet federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 7/24/25 |